Trilliant’s Corporate Commitment to Sustainability Reinforced with Certifications, Awards
28.8.2023 02:00:00 EEST | Business Wire | Press release
Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, continues to focus on its commitment to sustainability for its customers and the company with new recertifications, awards and assessments.
Trilliant previously announced its Integrated Management System was recertified to ISO 9001:2015 and ISO 14001:2015. Recently, DEKRA Audits has also recertified Trilliant in the following areas, solidifying Trilliant’s commitment to sustainable business operations:
- ISO 27001:2013 standard for information security management systems (ISMS): ISO 27001 is the world's best-known standard for ISMS and defines requirements an ISMS must meet. The standard provides companies with guidance for establishing, implementing, maintaining, and continually improving an information security management system. Conformity with ISO/IEC 27001 means that an organization or business has put in place a system to manage risks related to the security of data owned or handled by the company, and that this system respects all the best practices and principles enshrined in this International Standard.
- ISO 45001:2018 standard for occupational health and safety (OH&S) management: ISO 45001:2018 specifies requirements for an OH&S management system. It gives guidance for its use to enable organizations to provide safe and healthy workplaces by preventing work-related injury and ill health, as well as by proactively improving its OH&S performance.
In June 2023, Trilliant was recertified for the ECORESPONSIBLE™ Certification, progressing to Level #2 (Performance). This certification in sustainable development management is part of an ongoing four-level improvement process, designed to help organizations improve their overall performance in economic, environmental, social and governance terms. By making strategic decisions regarding sustainable development through their ECORESPONSIBLE practices, organizations show their tangible contribution to sustainable development. In doing so, they reduce their ecological impact and improve their value chain.
Trilliant is also the recipient of a 2022 EcoVadis Silver medal and placed in the top 19 percent within its industry. EcoVadis has grown to become the world’s largest and most trusted provider of business sustainability ratings, creating a global network of more than 100,000+ rated companies. EcoVadis medals recognize companies that have completed the EcoVadis assessment process and demonstrated a relatively strong management system that addresses sustainability criteria, as outlined in the EcoVadis methodology. Companies must also meet specific licensing and eligibility criteria.
Trilliant’s office in Granby, Québec, was recently recognized by the City of Granby with an Environmental Recognition Award. This awards honors citizens, non-profit organizations, businesses, industries and educational institutions of the City of Granby who have made an outstanding contribution to the community and its reputation through their commitment and achievements in environmental and sustainable development matters. Trilliant was honored in the Sustainable Industry category for its ECORESPONSIBLE™ certification.
Sustainability: A key pillar of Trilliant’s strategy
Trilliant understands that not only is sustainability important for future generations, but that utilities and cities want to know their vendors and suppliers are dedicated to social responsibility. To demonstrate its commitment, Trilliant is a participating member of the UN Global Compact. The compact is a global call to action for companies to support the UN’s social development goals (SDGs). Trilliant is focused on four of those goals, which continue to guide the company’s strategy and align with its mission: affordable and clean energy; sustainable cities and communities; responsible consumption and production; and climate action.
“Our commitment to sustainability in our work has never been clearer,” said Andy White, Chairman and CEO, Trilliant. “Our certifications and awards enable Trilliant to be accountable and ensure that our goals and practices have a positive impact on our customers, partners and all our stakeholders. We’re also proud of our global team members who are energized to engage on initiatives that are aligned with the UN SDGs.”
As the company looks ahead, it has engaged COESIO — third-party sustainability experts — to finalize and support the implementation of Trilliant's Net Zero plan. Trilliant will share its progress and impact in a future update.
About Trilliant
Trilliant® empowers the global energy industry with the only device-agnostic communications platform that enables utilities and cities to deploy any application securely and reliably on one powerful network. Our purpose-built portfolio is designed to offer the power of choice, without risk of customers being “locked in” with one technology provider or meter manufacturer. We are proud to offer mission-critical solutions that support AMI, Data & Analytics, Smart Metering, Smart Grids and Smart Cities. Customers worldwide benefit from Trilliant’s unique combination of flexibility, sustainability and scalability that connects utilities and cities to the IIoT and a more strategic path to the Energy Transition. Visit us at www.trilliant.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230827921449/en/
Contact information
Tracey Mitchell
tracey.mitchell@trilliant.com
Cindy Watson/Anita Wong
StrategicAmpersand
TrilliantPR@stratamp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
